If you are:
Possibly Safe: INSUFFICIENT HUMAN DATA AVAILABLE; NO DEVELOPMENTAL TOXICITY SEEN IN ANIMALS
Precaution: INSUFF DATA AVAIL; MOLECULAR WT LOW ENOUGH FOR POSSIBLE BREASTMILK EXCRETION
An adult over 60:
management or monitoring precaution: Cardiac-QT and PR prolongation risks. Use electrocardiogram (ECG) monitoring in patients with congestive heart failure, bradycardia, AV block, underlying heart disease, the elderly and in patients who are renally impaired. Correct hypokalemia and hypomagnesemia before administering. Renal-The major active metabolite, hydrodolasetron, is renally excreted. Monitoring the ECG in the elderly is recommended.
Giving dolasetron-tablet to a child under 12:
Severe Precaution: Caution with cardiac structure or conduction abnormality. Reports of SVT, MI, death in pediatrics.
Severe Precaution: Cardiac arrhythmia risk. Safety & efficacy not established in pediatrics age < 2 years.